<DOC>
	<DOCNO>NCT00870350</DOCNO>
	<brief_summary>Open-label , randomize , multi-centre study 400 subject , divide two group , receive Td5ap Td1aP single injection . We describe immune response safety profile combine vaccine booster .</brief_summary>
	<brief_title>An Immunogenicity Safety Study Tetanus , Diphtheria Acellular Pertussis Vaccine Booster</brief_title>
	<detailed_description>The vaccine study COVAXIS ( Td5ap ) , Sanofi Pasteur Canada , diTekiBooster ( Td1aP ) , Statens Serum Institut , Denmark . The primary objective study describe immune response diphtheria toxin , tetanus toxoid , pertussis toxin , filamentous haemagglutinin ( FHA ) , fimbria 2/3 pertactin four week immunization Td1aP Td5ap . The secondary objective include : - describe safety fith dose DTP vaccine 14-15 year-old child observe systemic local adverse reaction - describe pre-booster antibody level - describe pre-booster post-booster IgG IgA level saliva - describe subpopulation pre-booster post-booster T cell immune response determine production cytokine - describe subpopulation pre-booster post-booster B cell immune response determine number effector memory B-cells The sample size 400 subject ( 200 group 1 200 group 2 ) . It open-label , randomize , multi-centre study group 1 receive Td5ap single injection group 2 receive Td1aP single injection . DTP antibody measure 28 day ( + 14 day ) Td5ap Td1aP vaccination . The proportion child positive IgG antibody response measure study arm . Sera test blindly establish ELISA method saliva sample analyze exploratory assay . In subpopulation cellmediated immunity analyze . The safety evaluation criterion percentage subject adverse event describe injection-site adverse reaction , systemic adverse event , daily temperature serious adverse event .</detailed_description>
	<mesh_term>Whooping Cough</mesh_term>
	<mesh_term>Tetanus</mesh_term>
	<mesh_term>Tetany</mesh_term>
	<mesh_term>Diphtheria</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>healthy subject 1415 year old eligible schoolleaving booster DTP receive complete primary vaccination 5component acellular pertussis vaccine ( DT5aPIPVHib ) 3 , 5 12 month age vaccinate 5component acellular pertussis vaccine ( Td5aPIPV Td5aP + IPV ) booster 5½ year age inform consent form sign subject parent ( ) /legal representative subject understand comply study procedure ( i.e . able read write Swedish ) female must provide agreement either sexually continent practice adequate contraceptive method ( intrauterine contraceptive device ( IUCD ) , hormonal contraceptive , condom adequate barrier contraception ) . acute febrile illness axillary temperature ≥38.0°C time vaccination receipt immunoglobulin within previous 3 month , immunosuppression ( e g evidence impair cell mediate immunity , receipt immunosuppressant drug within previous 3 month receipt systemic corticosteroid give daily alternate day ≥20 mg/day prednisone equivalent &gt; 14 day within past 30 day ) receipt nonstudy vaccine past 30 day evolve encephalopathy attributable another identifiable cause within 7 day administration previous dose vaccine booster vaccination tetanus , low dose diphtheria acellular pertussis vaccine since booster vaccination 5½ year age previous clinical bacteriological diagnosis diphtheria , tetanus pertussis hypersensitivity component study vaccine current participation clinical trial participation clinical trial previous month inability adhere protocol , include plan move area severe chronic disease family history congenital hereditary immunodeficiency sever thrombocytopenia coagulation disorder would contraindicate intramuscular injection medical condition , opinion investigator , might interfere evaluation study objective .</criteria>
	<gender>All</gender>
	<minimum_age>14 Years</minimum_age>
	<maximum_age>15 Years</maximum_age>
	<verification_date>March 2009</verification_date>
	<keyword>immunogenicity</keyword>
	<keyword>safety</keyword>
	<keyword>tetanus</keyword>
	<keyword>diphtheria</keyword>
	<keyword>acellular</keyword>
	<keyword>pertussis</keyword>
	<keyword>vaccine</keyword>
	<keyword>booster</keyword>
	<keyword>adverse event</keyword>
	<keyword>adverse reaction</keyword>
	<keyword>DT1aP</keyword>
	<keyword>DT5ap</keyword>
	<keyword>FHA</keyword>
	<keyword>fimbria</keyword>
	<keyword>pertactin</keyword>
	<keyword>SMI</keyword>
	<keyword>Smittskyddsinstitutet</keyword>
	<keyword>Immune response safety profile Tdap booster</keyword>
</DOC>